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BK  virus  (BKV)  causes  BKV nephritis  in  renal  transplant  patients  and  contributes  signiﬁcantly  to the
increase  of  probability  of  graft loss.  BKV,  being  latent  in  the  urogenital  tract,  is likely  to  be transported
with  the  donor  kidney  to recipients  and following  reactivation  replicates  in  the nucleus  of renal  epithelial
tubular  cells.  BKV daughter  viruses  are  released  and  enter  other  renal  epithelial  cells  to spread  infection.
There  are  still a lot  of  unknown  factors  about  the  mechanism  and  kinetics  of BKV  infection.  The  treat-
ment  of  BKV infection,  with  exception  of reduction  in  immunosuppression  which  increases  the  risk  of
allograft  rejection,  is  almost  exclusively  limited  to application  of anti-viral  drugs  with  rather  inconsistentellular receptor
enal transplantation
results.  The  shortcomings  of anti-viral  therapies  demand  the  understanding  of early  steps  of infection  of
permissive  cells  by BK virus  in hope  that  adequate  interventional  therapies  preventing  infection  of  cells
with  BK virus  could  be developed.  This  review  describes  the BKV  entry  in target  human  cells,  intracellular
trafﬁcking  pathways  of  BKV  particles  and  potential  therapeutic  implications  based  on  understanding  of
mechanisms  of  BKV  infection  of renal  cells.
©  2015  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. General information about BK virus
BKV is a small double-stranded DNA virus assigned to the
olyomaviridae family, which other well-known members include
he JC virus (JCV) and simian virus SV40 [1]. Polyomaviruses are
biquitous viruses with high seroprevalence rates in general popu-
ation. Following primary infection, the virus remains latent in the
ost in different sites, particularly the kidneys and uroepithelial
ells. Reactivation from latency may  occur in normal subjects with
symptomatic viruria, while it can be associated with nephropathy
n kidney transplant recipients [2]. It has been shown that during
mmunosuppression, virus reactivation causes cytopathic changes
n the uroepithelium, and consequently, there is increased shed-
ing of BKV in the urinary tract [3]. This review discusses the clinical
spect of BKV nephropathy as well as mechanism of renal cells
nfection.
. BK virus associated nephropathy– clinical aspect
.1. Clinical presentation
Declining renal allograft function is the most common presen-
ation. The patient is asymptomatic with progressive rise in serum
reatinine [4]. Interstitial nephritis associated with BKV infection
s difﬁcult to distinguish from acute cellular rejection. Subsequent
brotic changes can contribute to chronic allograft nephropathy.
scending infection along uroepithelium from urinary bladder has
een reported to cause ureteral stenosis and subsequently allo-
raft obstruction. Higher level of BKV has also been associated with
emorrhagic cystitis, and may  be the initial presentation of BKV
ephropathy in renal transplant recipient [4].
.2. Diagnosis
Decoy cells have been observed in urine cytology of patients
ith BKV Nephropathy (BKVN). These cells originated from infected
enal tubular cells with nuclei altered by viral inclusions. The pres-
nce of decoy cells is a sensitive (100%) measure but has a low
ositive predictive value of 29% for the diagnosis of BKVN [5].
uantiﬁcation of viral load in the plasma and urine with either
iral DNA or viral protein-1 (VP-1) mRNA has been used to diag-
ose BKVN [5]. There is a general agreement that BK viruria of
reater than 107 BKV copies/ml of urine and BKV viremia of 104
opies BKV/ml of plasma are typical in patients with biopsy-proven
KVN [3]. A transplant kidney biopsy remains the gold standard
or diagnosing BKVN. Pathologic ﬁndings of infection include viral
ytopathic changes in the tubular epithelium, glomeruli, and col-
ecting ducts with interstitial inﬂammation and varying degrees of
ubular atrophy or ﬁbrosis [5]. These histological changes can be
ocal or isolated to the medulla and missed on one third of biopsies
f only a single core is evaluated [6]. Therefore, at least two cores
ncluding the medulla should be examined. If there are no cyto-
athic changes on histology and there is a high clinical suspicion,
hen adjunctive tests such as immunohistochemistry staining with
ross-reacting SV40 large T antigen should be performed since the
istopathology of BKV infections may  be misinterpreted as acute
ejection [6].
.3. Treatment
The goal in treating BKV infection is to eliminate the virus
hile preserving renal function and preventing acute or chronicejection [5]. The principal treatment of BKV nephropathy is reduc-
ion in immunosuppression, which carries a risk of acute allograft
ejection [4,6]. Various strategies for altering immunosuppressive
herapy include discontinuation of an agent, decreasing an agent,al Virology 71 (2015) 59–62
switching immunosuppressant within the same class or to another
class, steroid avoidance, or adjunctive therapies [5,6]. Antiviral
therapy with leﬂunomide or cidofovir has been used in conjunction
with decreasing immunosuppression in some cases [5]. Therapy
with rituximab the anti-CD20 mAb  has also been used with promis-
ing results. The administration of IVIG with concomitant reduction
in immunosuppressive therapy has been successful; however, efﬁ-
cacy of IVIG is unclear [5]. Close monitoring of BKV DNA and renal
function with any therapy is critical to improving outcome for
patients with BKV infection [5]. Failure to clear BKV leads to worse
graft function and outcomes. Monitoring should be performed with
BKV PCR, until the viral level is undetectable or at least falls below
the threshold value that is associated with BKV nephropathy [6].
On the basis of kinetic models and prospective monitoring, viremia
clears in 7–20 weeks, but the initial decrease may  be delayed by
4–10 weeks after immunosuppression reduction [6].
3. Mechanism of infection of renal cells: entry into cells
and intracellular trafﬁcking
The treatment of BKV infection, with exception of reduction in
immunosuppression which increases the risk of allograft rejection,
is almost exclusively limited to application of anti-viral drugs with
rather inconsistent results. The shortcomings of anti-viral therapies
demand the understanding of early steps of infection of permissive
cells by BK virus in hope that adequate interventional therapies
preventing infection of cells with BK virus could be developed.
The efforts to uncover the mechanisms of BK virus infection have
employed the preparations of human BK virus and cultured per-
missive cells. It is beneﬁcial to use human renal proximal tubular
epithelial cells (HRPTEC) since tubular epithelial cells are the main
natural target of BKV infection [7,8].
The ﬁrst indication that BK virus might enter target cells via
caveolae-mediated endocytosis came from studies of BKV infec-
tion of permissive Vero cells derived from the kidney of an African
green monkey [9]. Studies employing Vero cells allowed elucidating
the early steps of BKV infection [10], but, since polyomaviruses are
notoriously species speciﬁc and since Vero cells is not a primary, but
an established aneuploid cell line, the mechanisms of entrance of
BK into human renal epithelial cells could be different. The nature of
host cells has a profound effect upon efﬁciency and consequences
of viral infection. Experiments carried out with primary HRPTEC
demonstrated that the depletion of cholesterol and decrease of
Caveolin-1 (Cav-1) levels by Cav-1 siRNA inhibited cellular infec-
tion by BK virus [11]. Electron microscopic study of patients with
BK allograft nephropathy revealed that BK virions appear to enter
the renal tubular cells in non-coated vesicles that are morphologi-
cally consistent with caveolae [12] (caveolin-containing lipid rafts)
which are small (diameter of 50–80 nm)  ﬂask-shaped plasma mem-
brane invaginations, enriched in sphingolipids and cholesterol.
Endocytosis of caveolin-containing lipid rafts occurs in the absence
of functional clathrin-coated pits and is a highly regulated process
[13]. BKV infection was not inhibited in HRPTEC transfected with
clathrin siRNA. The colocalization of labeled BKV particles with Cav-
1 and absence of signiﬁcant colocalization with clathrin, as revealed
by ﬂuorescent microscopy and cross-correlation spectroscopy [14],
further supports the conclusion that caveolar endocytosis is critical
for BK virus infection of human renal epithelial cells [11].
The BKV passage through the endoplasmic reticulum (ER) on the
way to nucleus [15]. Co-incubation of HRPTEC with BKV and micro-
tubule disrupting agents prevented BKV infection [16]. It appears
that after endocytosis via caveolae BKV particles are transported
along the microtubules. This process requires the dynamicity of
microtubules to be intact, but seems to be independent of motor
protein dynein activity. In HRPTEC BKV particles are found in the ER
 Clinic
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t 6–8 h after infection. Even though in morphological study with
uman patients the endosomes carrying virions appeared to fuse
ith a system of smooth vesicles and tubules that communicated
ith rough ER and was continuous with the Golgi system (GA) [12],
 detailed analysis of intracellular trafﬁcking pathways in HRPTEC
evealed that BKV particles completely bypass the GA [16]. BKV
nfection of Vero cells was also sensitive to nocodazole-induced
isassembly of the microtubule network for the initial 8 h follow-
ng virus binding [17]. After that BKV particles enter the nucleus and
ollowing viral replication daughter viruses are delivered to other
ells using the same cell entering and intracellular trafﬁcking path-
ays. As a result, BKV infections expands and BKVN progresses.
KV course of infection in HRPTEC seemed to be relatively slow
ith process taking at least 24–48 h.
. Cellular determinants of BK virus infection
The ﬁrst step of infection is the interaction between the viral
article and target cells. All polyomaviruses utilize some kind
f receptor molecules which present cellular determinants for
nteraction with viral particle. In pioneering work by the Atwood
aboratory an N-linked glycoprotein containing alpha(2,3)-linked
ialic acid was reported to constitute a critical component of
he cellular receptor for BKV [18]. Site-speciﬁc mutagenesis, cou-
led with infectivity assays, allowed to generate a subset of
KV mutants deﬁcient in binding to Vero cells and propose
he existence of oligosaccharide receptor binding pocket on VP-
 [19]. Viral entry of not only BKV, but also JC virus (another
uman polyomavirus, which causes progressive multifocal leu-
oencephalopathy) is dependent on the ability to interact with
ialic acid [20]. The nature of the sialyted glycoprotein, which
erves as a receptor for BKV, remains to be uncovered. Since JC
irus uses serotonergic receptor 5HT2AR to infect human glial cells
21], it is possible that the BKV might also utilize a G-protein cou-
led receptor to enter renal epithelial cells. Polyomaviridae family
f viruses displays a substantial variability with regard to their
ellular receptors and have been shown to utilize molecules pre-
iously unknown to possess virus-related activities. The protein
omponent of receptor of mouse polyomavirus (mPyV) appears
o be 41 integrin [20]. In innovative work by the Imperi-
le laboratory, sialyted glycosphyngolipid structures gangliosides
D1b and GT1b were also identiﬁed as receptors for BK virus
15].
. Therapeutic implications and future directions of
reatment
Although potent immunosuppressive therapies have proved to
e useful for acute and chronic rejection after renal transplanta-
ion, they are a risk factor for the progression of latent BKV to
KVN. Retransplantation after renal allograft loss to BKVN remains
 treatment option for some patients [22]. There are more than
00,000 patients with end stage renal disease waiting for kid-
ey transplantation due to scarcity of organs which means loss
f an allograft can put patients on dialysis for years. Moreover,
he cost of retransplantation could exceed $500,000 per patient in
ome centers which includes laboratory charges for viral load test-
ng, dialysis or other costs associated with managing BKV-related
enal failure. Even after retransplantation there is a rate of recur-
ence of BKV in the new transplant [23]. Thus, BKVN remains major threat to the success rate of most transplant centers,
verall allograft longevity, and contributes signiﬁcantly to esca-
ation of health care costs in USA and worldwide. The treatment
f BKVN pins on reducing immunosuppression and the treat-al Virology 71 (2015) 59–62 61
ment protocol is center speciﬁc. In general stopping or reducing
antimetabolites like mycophenolate or azathioprine is common,
which is usually combined with reducing calcinurin inhibitors.
When immunosuppression has been reduced to the limit and still
there is continuous decline of renal function antiviral therapy is
initiated. Even with successful management of BKVN, the treat-
ment is associated with an overall 1.69 hazard ratio of allograft
loss. In view of limited success of routine anti-viral therapy and
risk of drug renal toxicity the future directions of treatment might
take advantage of the knowledge of early steps of BKV entry into
the target cells. As described above, it has been established that
BKV is taken up into cells via caveolae-associated endocytosis and
that this is critical for BKV infection of HRPTEC [11,16]. Also, it
seems very likely, that BKV uses unidentiﬁed sialyted glycopro-
tein as a cellular receptor to infect target cells. We  believe that
uncovering the identity of this glycoprotein will open up thera-
peutic approaches to interfere with binding of BKV to its cellular
receptor. Human polyomavirus receptors may  represent targets for
therapeutic intervention to prevent and treat polyomavirus related
diseases [24]. Thus, studies focusing on uncovering of the nature of
BKV receptor in human renal epithelial cells represent a signiﬁ-
cant and clinically relevant area of investigation with immediate
translational potential.
The other possible novel direction of therapeutic intervention
of BKVN is interfering with BKV caveolar-mediated endocytosis. It
is probable that agents, which are used in a clinical situation as
cholesterol lowering agents, might decrease caveolae, interfering
with BKV internalization and decreasing BKV infection of human
renal epithelial cells. The ability of 3-hydroxy-3-methyl-glutaryl
coenzyme A reductase inhibitors (statins), which is routinely used
to treat hypercholesterolemia, to repress BK virus entry path-
ways in HRPTEC and, correspondingly, prevent BKV infection
was demonstrated [25]. In this study HRPTEC were co-incubated
with BKV and pravastatin, one of the hydrophilic statins. Both
the percentage of BKV infected cells and the large T antigen
expression, which suggested BKV infection, were signiﬁcantly
decreased in HRPTEC pretreated and co-incubated with pravas-
tatin [25]. The pravastatin’s inhibitory effect could be explained
by a dramatic depletion of Cav-1, a critical element of caveo-
lae, which happens due to inhibition of cholesterol synthesis.
These data suggest that statins, acting via depletion of Cav-1,
could prevent caveolar-dependent BKV entry and repress BKV
infection of HRPTEC. Even though decrease of Cav-1 was  demon-
strated in pravastatin-treated HRPTEC [25], it must be taken
into consideration that non-cholesterol mechanisms of statin
action have been proposed [26]. Inhibition of the mevalonate
pathway, which is inhibited by statins, also affects synthesis of
isoprenoid precursors for prenylation of a number of signaling
molecules, including Ras family of proteins [27]. The concentra-
tions of statins needed to inhibit protein prenylation are much
higher than those which prevent cholesterol synthesis suggest-
ing that cells are likely to maintain the prenylation pathway at
the expense of cholesterol synthesis [27]. Regardless their mech-
anism of action, statins unlikely to be efﬁcient against progressed
BKVN. Accordingly, the treatment with statins should be consid-
ered as soon as possible following detection of BKV viruria or
viremia and it may  be already too late when BKVN is diagnosed
by renal biopsy, because at the time of diagnosis, BKV infec-
tion would be established by now and BKV will spread to other
cells.
Recently it was  demonstrated that viral attachment proteins
coupled to beads can be used to screen large families of compounds
that possessed similar chemical space as sialic acid for their ability
to bind the virus. The high throughput search revealed several gallic
acid-based small compounds which reduced binding and infection
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f Vero cells by BKV [28]. These studies could set the base for the
evelopment of virion speciﬁc antagonists to treat BKV infection.
. Conclusion
Nephritis induced by BKV, a non-enveloped double-stranded
eoxyribonucleic acid (DNA) polyomavirus, remains a severe prob-
em after renal transplantation. In view of limited success of routine
nti-viral therapy the future directions of treatment should take
dvantage of the knowledge of early steps of BKV entry into the
arget cells. Caveolar endocytosis is critical for BKV infection of
uman renal tubular epithelial cells. An N-linked glycoprotein or
anglioside containing alpha (2,3)-linked sialic acid is a component
f the cellular receptor for BKV. Novel potential directions of ther-
peutic intervention of BKV nephritis are strategies based either
n prevention of binding of BKV particles to cellular receptors on
enal tubular epithelial cells or interference of caveolin-mediated
ndocytosis and intracellular trafﬁcking of BKV. The uncovering of
he nature of BKV receptor in human renal epithelial cells, develop-
ent of statin-based strategies to prevent caveolar-dependent BKV
ntry and depiction of small molecules - virion speciﬁc antagonists,
ould have immediate translational potential.
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